Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

August 5, 2022

Acadia Pharmaceuticals receives CRL for sNDA for NUPLAZID to treat ADP

Acadia Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) on its supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin).

Acadia Pharmaceuticals receives CRL for sNDA for NUPLAZID to treat ADP